(Total Views: 224)
Posted On: 12/29/2019 3:48:56 PM
Post# of 36566
This is the latest I know of -
From 12/10/19 PR
NGIO, a majority owned subsidiary of Generex, is being spun out of the parent company to form a new, publicly traded oncology company focused on modulation of the immune system to treat cancer. Generex management is in the process of filing the requisite legal documents, conducting the necessary 2-year audits, preparing the S1 filing, and planning to initiate operations as a new public company.
Buildit wrote -
Yes, Msowid... the NGIO spin should be huge. But no updates since that call, if I'm correct?
Read More: https://investorshangout.com/post/newpost/622...z69WzJZPxb
From 12/10/19 PR
NGIO, a majority owned subsidiary of Generex, is being spun out of the parent company to form a new, publicly traded oncology company focused on modulation of the immune system to treat cancer. Generex management is in the process of filing the requisite legal documents, conducting the necessary 2-year audits, preparing the S1 filing, and planning to initiate operations as a new public company.
Buildit wrote -
Yes, Msowid... the NGIO spin should be huge. But no updates since that call, if I'm correct?
Read More: https://investorshangout.com/post/newpost/622...z69WzJZPxb
(0)
(0)
